Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech Portfolio News / By Karina Tin September 27, 2021 Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech Read More »
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes Portfolio News / By Karina Tin September 22, 2021 Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes Read More »
ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor Portfolio News / By Karina Tin September 21, 2021 ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor Read More »
NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021 Portfolio News / By Karina Tin September 16, 2021 NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021 Read More »
Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates Portfolio News / By Karina Tin September 8, 2021 Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates Read More »
Ribon Therapeutics Announces Key Management Promotions Portfolio News / By Karina Tin September 1, 2021 Ribon Therapeutics Announces Key Management Promotions Read More »
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies Portfolio News / By Karina Tin August 25, 2021 eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies Read More »
Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer Portfolio News / By Karina Tin August 24, 2021 Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer Read More »
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research Portfolio News / By Karina Tin August 23, 2021 NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research Read More »
Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer Portfolio News / By Karina Tin August 17, 2021 Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer Read More »
